Patents by Inventor Philippe G. Nantermet

Philippe G. Nantermet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030216301
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: 1
    Type: Application
    Filed: May 1, 2003
    Publication date: November 20, 2003
    Inventors: James C. Barrow, Philippe G. Nantermet, Harold G. Selnick
  • Publication number: 20030158218
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: 1
    Type: Application
    Filed: December 6, 2002
    Publication date: August 21, 2003
    Inventors: Philippe G. Nantermet, Harold G. Selnick, James C. Barrow, Craig Coburn, Christopher Burgey, Kyle A. Robinson, Terry Alan Lyle
  • Patent number: 6544982
    Abstract: A thrombin receptor antagonist having the formula useful for inhibiting the aggregation of blood platelets. The compounds can be used in a method of acting upon a thrombin receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to a mammal, preferably a human.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: April 8, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Harold G. Selnick, Philippe G. Nantermet, James C. Barrow, Roger M. Freidinger, Thomas Connolly
  • Patent number: 6515023
    Abstract: A thrombin receptor antagonist having the formula useful for inhibiting the aggregation of blood platelets. The compounds can be used in a method of acting upon a thrombin receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to a mammal, preferably a human.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: February 4, 2003
    Assignee: Merck & Co., Inc.
    Inventors: James C. Barrow, Philippe G. Nantermet, Harold G. Selnick, John H. Hutchinson, Michael J. Breslin, Kristen L. Glass, Thomas M. Connolly, Andrew Stern
  • Patent number: 6515011
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, e.g. where R3 is —CH2NH2, —CH2CH2NH2, or —CH2NHC(O)OC(CH3)3.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: February 4, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Harold G. Selnick, James C. Barrow, Philippe G. Nantermet, Peter D. Williams, Kenneth J. Stauffer, Philip E. Sanderson, Kenneth E. Rittle, Matthew M. Morrissette, Catherine M. Wiscount, Lekhanh O. Tran, Terry A. Lyle, Donnette D. Staas
  • Publication number: 20020119992
    Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: 1
    Type: Application
    Filed: December 18, 2001
    Publication date: August 29, 2002
    Inventors: Harold G. Selnick, James C. Barrow, Philippe G. Nantermet, Peter D. Williams, Kenneth J. Stauffer, Philip E. Sanderson, Kenneth E. Rittle, Matthew M. Morrissette, Catherine M. Wiscount, Lekhanh O. Tran, Terry A. Lyle, Donnette D. Staas
  • Patent number: 6403612
    Abstract: A thrombin receptor antagonist having the formula or a pharmaceutically acceptable salt thereof, useful for inhibiting the aggregation of blood platelets. The compounds can be used in a method of acting upon a thrombin receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to a mammal, preferably a human.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: June 11, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Philippe G. Nantermet, James C. Barrow, Harold G. Selnick
  • Publication number: 20020007045
    Abstract: A thrombin receptor antagonist having the formula 1
    Type: Application
    Filed: January 30, 2001
    Publication date: January 17, 2002
    Inventors: James C. Barrow, Philippe G. Nantermet, Harold G. Selnick, John H. Hutchinson, Michael J. Breslin, Kristen L. Glass, Thomas M. Connolly, Andrew Stern
  • Patent number: 6339090
    Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: January 15, 2002
    Assignee: Merck & Co., Inc.
    Inventors: James C. Barrow, Harold G. Selnick, Philippe G. Nantermet
  • Publication number: 20010044454
    Abstract: A thrombin receptor antagonist having the formula 1
    Type: Application
    Filed: January 30, 2001
    Publication date: November 22, 2001
    Inventors: Philippe G. Nantermet, James C. Barrow, Harold G. Selnick
  • Patent number: 6043382
    Abstract: A method for esterifying C13 deoxy taxoid intermediates employs three steps, i.e., oxygenation of the C13 deoxy taxoid intermediate to produce a C13 enone taxoid intermediate; reduction of the C13 enone to produce an alcohol; followed by esterification of the C13 alcohol. Key intermediates include C13 deoxy taxoids; C13 enone substituted taxoids; and C1-C2 cyclo carbonate esters of taxoids.
    Type: Grant
    Filed: July 28, 1998
    Date of Patent: March 28, 2000
    Assignee: The Scripps Research Institute
    Inventors: K.C. Nicolaou, Philippe G. Nantermet, Rodney K. Guy, Hiroaki Ueno
  • Patent number: 5817822
    Abstract: The present invention relates to the alpha-(N-substituted pyrrolidinyl and piperidinyl) alpha-(arysulfonamido)-aceto-hydroxamic acids of formula I ##STR1## wherein R represents acyl derived from a carboxylic acid, from a carbonic acid or from a carbamic acid; or R represents (lower alkyl, aryl-lower alkyl or aryl)-sulfonyl, di-(aryl-lower alkyl or alkyl)-aminosulfonyl, or aryl-lower alkyl; Ar represents carbocyclic aryl, heterocyclic aryl or biaryl; R.sub.1 and R.sub.2 represent independently hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy, acyloxy, lower alkoxy-lower alkoxy, trifluoromethyl or cyano; or R.sub.1 and R.sub.
    Type: Grant
    Filed: January 24, 1997
    Date of Patent: October 6, 1998
    Assignee: Novartis Corporation
    Inventors: Philippe G. Nantermet, David T. Parker, Lawrence J. MacPherson
  • Patent number: 5786489
    Abstract: A method for esterifying C13 deoxy taxoid intermediates employs three steps, i.e., oxygenation of the C13 deoxy taxoid intermediate to produce a C13 enone taxoid intermediate; reduction of the C13 enone to produce an alcohol; followed by esterification of the C13 alcohol. Key intermediates include C13 deoxy taxoids; C13 enone substituted taxoids; and C1-C2 cyclo carbonate esters of taxoids.
    Type: Grant
    Filed: April 1, 1996
    Date of Patent: July 28, 1998
    Assignee: The Scripps Research Institute
    Inventors: Kyriacos C. Nicolaou, Philippe G. Nantermet, Rodney K. Guy, Hiroaki Ueno
  • Patent number: 5760240
    Abstract: Bioactive ABC taxoids accessible by convergent synthesis have an intact AB ring framework of taxol, including the C.sup.13 side chain, and an aromatic C ring which substitutes for the CD ring system found on native taxol. The aromatic C ring may be substituted or unsubstituted. MPT derivatives of ABC taxoids are also disclosed.
    Type: Grant
    Filed: September 13, 1995
    Date of Patent: June 2, 1998
    Assignee: The Scripps Research Institute
    Inventors: K. C. Nicolaou, Christopher F. Claiborne, Philippe G. Nantermet, Elias A. Couladouros, Erik J. Sorenson
  • Patent number: 5750691
    Abstract: Transformations of taxol, baccatin III and of 10-deacetyl baccatin III provide access to novel taxol analogs and key intermediates thereto.
    Type: Grant
    Filed: August 7, 1995
    Date of Patent: May 12, 1998
    Assignee: The Scripps Research Institute
    Inventors: K. C. Nicolaou, Philippe G. Nantermet, Rodney K. Guy, Hiroaki Ueno
  • Patent number: 5504222
    Abstract: A method for esterifying C13 deoxy taxoid intermediates employs three steps, i.e., oxygenation of the C13 deoxy taxoid intermediate to produce a C13 enone taxoid intermediate; reduction of the C13 enone to produce an alcohol; followed by esterification of the C13 alcohol. Key intermediates include C13 deoxy taxoids; C13 enone substituted taxoids; and C1-C2 cyclo carbonate esters of taxoids.
    Type: Grant
    Filed: February 8, 1994
    Date of Patent: April 2, 1996
    Assignee: The Scripps Research Institute
    Inventors: K. C. Nicolaou, Philippe G. Nantermet, Rodney K. Guy, Hiroaki Ueno
  • Patent number: 5481007
    Abstract: Bioactive ABC taxoids accessible by convergent synthesis have an intact AB ring framework of taxol, including the C.sup.13 side chain, and an aromatic C ring which substitutes for the CD ring system found on native taxol. The aromatic C ring may be substituted or unsubstituted. MPT derivatives of ABC taxoids are also disclosed.
    Type: Grant
    Filed: February 23, 1994
    Date of Patent: January 2, 1996
    Assignee: The Scripps Research Institute
    Inventors: K. C. Nicolaou, Christopher F. Claiborne, Philippe G. Nantermet, Elias A. Couladouros, Erik J. Sorensen
  • Patent number: 5461169
    Abstract: The total synthesis of taxol employs a convergent synthetic plan. The synthetic plan may also be employed to produce a large number of taxol analogs. Taxol analogs having skeletal extensions are inaccessible by modification of the natural product but are readily produced by employing the convergent synthetic plan herein.
    Type: Grant
    Filed: February 16, 1994
    Date of Patent: October 24, 1995
    Assignee: The Scripps Research Institute
    Inventors: K. C. Nicolaou, Zhen Yang, Jin-Jun Liu, Hiroaki Ueno, Philippe G. Nantermet
  • Patent number: 5440057
    Abstract: Transformations of taxol, baccatin III and of 10-deacetyl baccatin III provide access to novel taxol analogs and key intermediates thereto.
    Type: Grant
    Filed: August 20, 1993
    Date of Patent: August 8, 1995
    Assignee: The Scripps Research Institute
    Inventors: K. C. Nicolaou, Philippe G. Nantermet, Rodney K. Guy, Hiroaki Ueno